Human Gene TherapyVol. 7, No. 3 News and CommentsUse of Safety-Modified Retroviruses to Introduce Chemotherapy Resistance Sequences into Normal Hematopoietic Cells for Chemoprotection During the Therapy of Breast Cancer: A Pilot Trial. M.D. Anderson Cancer Center, Houston, TexasSTUDY CHAIRMAN Albert B. Deisseroth, STUDY CO-CHAIRMAN Frankie Holmes, Gabriel Hortobagyi, and Richard ChamplinSTUDY CHAIRMAN Albert B. DeisserothSearch for more papers by this author, STUDY CO-CHAIRMAN Frankie HolmesSearch for more papers by this author, Gabriel HortobagyiSearch for more papers by this author, and Richard ChamplinSearch for more papers by this authorPublished Online:20 Mar 2008https://doi.org/10.1089/hum.1996.7.3-401AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byMobilization for Gene Therapy20 December 2011Gene therapy: theoretical and bioethical conceptsArchives of Medical Research, Vol. 34, No. 4Specific myeloprotection via multidrug resistance 1 gene controlled by aminopeptidase N myeloid promoterChinese Science Bulletin, Vol. 47, No. 19Evaluation of an Inhibitor of DNA Methylation, 5-aza-2′-Deoxycytidine, for The Treatment of Lung Cancer and the Future Role of Gene Therapy11 April 2006Gene Therapy in the Treatment of Human CancerUpdate on the Use of Genetically Modified Hematopoietic Stem Cells for Cancer TherapyCloning of aminopeptidase N promoter and its activity in hematopoietic cell and different tumor cell linesChinese Science Bulletin, Vol. 46, No. 19Generation of Dual Resistance to 4-Hydroperoxycyclophosphamide and Methotrexate by Retroviral Transfer of the Human Aldehyde Dehydrogenase Class 1 Gene and a Mutated Dihydrofolate Reductase GeneMolecular Therapy, Vol. 3, No. 1High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future TrendsClinical Breast Cancer, Vol. 1, No. 3In vitro study on the cloning and transduction of human O6-methylguanine-DNA-methyltransferase cDNA into human umbilical cord blood CD34+ cellsChinese Journal of Cancer Research, Vol. 12, No. 2Gene therapy for cancerEuropean Journal of Cancer, Vol. 35, No. 14Gene therapy for cancerEuropean Journal of Cancer, Vol. 35, No. 6Advances in cancer gene therapy25 February 2005 | Expert Opinion on Therapeutic Patents, Vol. 9, No. 6Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancerPathology & Oncology Research, Vol. 5, No. 1Retroviral Vector-Modified Bone Marrow Stromal Cells Secrete Biologically Active Factor IX In Vitro and Transiently Deliver Therapeutic Levels of Human Factor IX to the Plasma of Dogs after Reinfusion Van Cherington, Gisela G. Chiang, Claire A. McGrath, Anita Gaffney, Theofanis Galanopoulos, Wilma Merrill, Christine B. Bizinkauskas, Michael Hansen, Joyce Sobolewski, Peter H. Levine, Joel S. Greenberger, and David R. Hurwitz20 March 2008 | Human Gene Therapy, Vol. 9, No. 10Gene therapy for pancreatic cancerSeminars in Surgical Oncology, Vol. 15, No. 1Efficient protection of cells from the genotoxicity of nitrosoureas by the retrovirus-mediated transfer of human O6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, Vol. 401, No. 1-2In Vitro Selection for K562 Cells with Higher Retrovirally Mediated Copy Number of Aldehyde Dehydrogenase Class-1 and Higher Resistance to 4-Hydroperoxycyclophosphamide Jan S. Moreb, Mark Schweder, Brian Gray, James Zucali, and Robert Zori20 March 2008 | Human Gene Therapy, Vol. 9, No. 5Retroviral Coexpression of Thymidylate Synthase and Dihydrofolate Reductase Confers Fluoropyrimidine and Antifolate ResistanceBiochemical and Biophysical Research Communications, Vol. 243, No. 1Immunotherapy and gene therapy for renal cell carcinomaUrologic Oncology: Seminars and Original Investigations, Vol. 3, No. 5-6Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy24 December 1996 | Proceedings of the National Academy of Sciences, Vol. 93, No. 26Gene therapy for cancer-in the dock, blown off course or full speed ahead?Cancer and Metastasis Review, Vol. 15, No. 3Gene therapy for cancer, the course aheadCancer and Metastasis Review, Vol. 15, No. 3 Volume 7Issue 3Feb 1996 InformationCopyright 1996, Mary Ann Liebert, Inc.To cite this article:STUDY CHAIRMAN Albert B. Deisseroth, STUDY CO-CHAIRMAN Frankie Holmes, Gabriel Hortobagyi, and Richard Champlin.Use of Safety-Modified Retroviruses to Introduce Chemotherapy Resistance Sequences into Normal Hematopoietic Cells for Chemoprotection During the Therapy of Breast Cancer: A Pilot Trial. M.D. Anderson Cancer Center, Houston, Texas.Human Gene Therapy.Feb 1996.401-416.http://doi.org/10.1089/hum.1996.7.3-401Published in Volume: 7 Issue 3: March 20, 2008PDF download